At AGC Biologics, we have developed more than 200 mammalian, bacteria and yeast-based processes, giving us the insight and experience necessary to develop and optimize parameters that are critical for achieving a high-quality, cost-effective manufacturing process for your product.
Developing an efficient, scalable, validated and cost-effective manufacturing process is essential for success in today’s competitive biologics markets. Whether you need assistance developing a new process, are improving existing processes, or are preparing to manufacture your product, you will benefit from our in-depth expertise.
AGC Biologics has successfully manufactured more than 200 biological products for pre-clinical studies through commercial approvals. Our global facilities across the United States, Europe and Asia offer multiple cGMP manufacturing lines and a variety of scales for mammalian cell culture and microbial fermentation.
The innovative design of our state-of-the art facilities allows for capacity and technological flexibility, while ensuring compliance with the strict biopharmaceutical regulations required for cGMP operations. Our dedicated and experienced technical teams are committed to helping each client meet their clinical and commercial goals.
Quality matters — to patients, regulatory authorities and our clients. AGC Biologics’ quality organization provides a comprehensive suite of Quality Assurance (QA) and Quality Control (QC) services. Highly trained Quality Units maintain strict quality systems at each of our manufacturing facilities to support our cGMP manufacturing efforts and to ensure compliance with all regulatory requirements.
Our US site is commercially approved by the U.S. Food and Drug Administration (FDA) for commercial cGMP production of two protein therapeutic products. In addition, our Copenhagen facility is approved by FDA, the European Medical Authorities and Health Canada for commercial cGMP manufacture of a protein product. Our facilities in Japan have been approved by the Japanese authorities (PMDA) for commercial manufacture of four products for the Japanese market.
Process validation is a critical and significant activity for customers preparing for commercial approval. AGC Biologics’ well-defined approach and supporting Quality Systems provide a straightforward path through process validation.
AGC Biologics
General Inquiries: contact@agcbio.com
Seattle (Headquarters)
21511 23rd Avenue SE
Bothell, WA 98021 USA
+1 425 485 1900
Berkeley
890 Heinz Avenue
Berkeley, CA 94710 USA
+1 425 485 1900
Copenhagen
Vandtaarnsvej 83B, DK-2860 Soeborg
Copenhagen, Denmark
CVR: 25950941
+45 7020 9470
AGC Biologics A/S, dba AGC Biologics, CVR no. 25950941
Heidelberg
Czernyring 22
69115 Heidelberg, Germany
+49 6221 90260
AGC Biologics GmbH Geschaeftsfuehrer / Managing Director: Dieter Kramer Sitz der Gesellschaft / Registered office: Heidelberg Registergericht / Register court: Mannheim HRB 335606
Yokohama
1150, Hazawacho, Kanagawa-ku
Yokohama 221-8755 Japan
+81 3 3218 5694
Chiba
10, Goikaigan, Ichihara City
Chiba 290-8566 Japan
+81 3 3218 5694
©2018 AGC Biologics. All Rights Reserved. Website Privacy Policy